Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.56 |
| ▸ | IDE | P14735 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL755309 | 0.79 | LMNA (0.60) | LMNAPTGS2ALDH1A1MAPTMEN1 | |
| SCHEMBL3575971 | 0.76 | G6PD (0.56) | G6PDIDEPTGS2ALDH1A1CA2 | |
| SCHEMBL863161 | 0.75 | PTGS2 (0.58) | LMNAPTGS2ALDH1A1MAPTCA2 | |
| SCHEMBL9988774 | 0.73 | LMNA (0.50) | G6PDIDELMNAPTGS2ALDH1A1 | |
| SCHEMBL303829 | 0.73 | CA1 (0.68) | G6PDIDELMNAPTGS2ALDH1A1 | |
| SCHEMBL12833714 | 0.73 | LMNA (0.50) | G6PDIDELMNAPTGS2ALDH1A1 | |
| SCHEMBL3752334 | 0.73 | LMNA (0.50) | G6PDIDELMNAPTGS2ALDH1A1 | |
| SCHEMBL585689 | 0.73 | PTGS2 (0.65) | LMNAPTGS2MEN1KMT2APTGS1 | |
| SCHEMBL709850 | 0.73 | LMNA (0.50) | G6PDIDELMNAPTGS2ALDH1A1 | |
| SCHEMBL30526834 | 0.73 | LMNA (0.50) | G6PDIDELMNAPTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910357-B1 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LTD (GB) | 2010-04-14 | — | — | EP | disclosed |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| US-20090163534-A1 | Indolizine Derivatives | ARGENTA DISCOVERY LIMITED (GB) | 2009-06-25 | — | — | US | disclosed |
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | ARGENTA DISCOVERY LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1931663-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | Argenta Discovery Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| EP-1910357-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007031747-A1 | IMDOLIZINE DERIVATIVES AS LIGANDS OF THE CRTH2 RECEPTOR | ARGENTA DISCOVERY LIMITED (GB) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006136859-A2 | INDOLI ZINE DERIVATIVES AND THEIR USE AS CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306109-A1 | Indolizine Derivatives as Ligands of the Crth2 Receptor | HRH4, HRH2, HRH3 | G6PD 3461/4885IDE 3527/4885LMNA 4224/4885 |
| US-20090163534-A1 | Indolizine Derivatives | HRH4, HRH2, NR1H2 | G6PD 2189/4885IDE 3326/4885LMNA 3422/4885 |
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | G6PD 1287/4885IDE 4634/4885LMNA 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.